Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report

BACKGROUND: The role of surgery in combined modality therapy for selected stage IV oligometastatic (OM) non-small cell lung cancer (NSCLC) is still controversial. Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) significantly improved the survival in adjuvant thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Han, Ning, Junwei, Li, Ziming, Divisi, Duilio, Rossi, Antonio, Cortellini, Alessio, Um, Sang-Won, Okuma, Yusuke, Lazzari, Chiara, Luo, Qingquan, Chen, Tianxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
iMDT Corner
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073747/
https://www.ncbi.nlm.nih.gov/pubmed/35529794
http://dx.doi.org/10.21037/tlcr-22-251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073747/
https://www.ncbi.nlm.nih.gov/pubmed/35529794
http://dx.doi.org/10.21037/tlcr-22-251

Ejemplares similares